A Phase 3 interventional study of SPM 962 and Ropinirole in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-05-23.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 3rd largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2009, is one of 20 in phase 3, and was the 23rd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 2 started in 2009.
This study's enrollment of 420 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Parkinson Disease by Otsuka Holdings Co., Ltd., this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 3, and was the 5th registered.
Otsuka Holdings Co., Ltd.’s Parkinson Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 12 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SPM 962 transdermal patch
Drug: SPM 962
Ropinirole tablet
Drug: Ropinirole
SPM962 placebo patch and Ropinirole placebo tab
Drug: Placebo
SPM 962 transdermal patch once a daily up to 36.0 mg/day
Ropinirole oral administration TID up to 15.0 mg/day
SPM962-placebo patch and Ropinirole-placebo tab
Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: baseline, 16 weeks after dosing
UPDRS Part 3 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing. UPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: baseline, 8 and 10 weeks after dosing
UPDRS Part 2 Sum Score
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing. UPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, 16 weeks after dosing
Off Time
Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day.
Time frame: Baseline, 16 weeks after dosing
Parkinson's Disease Sleep Scale-2 (PDSS-2)
Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement.
Time frame: Baseline, 16 weeks after dosing
On Time
Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.
Time frame: Baseline, 16 weeks after dosing
On Time Without Dyskinesia Disturbing Daily Activities
Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.
Time frame: Baseline, 16 weeks after dosing
On Time With Dyskinesia Disturbing Daily Activities
Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time).
Time frame: Baseline, 16 weeks after dosing
Effective Rate in UPDRS Part 3 Sum Score
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.
Time frame: Baseline, 16 weeks after dosing
Effective Rate in UPDRS Part 2 Sum Score
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.
Time frame: Baseline, 16 weeks after dosing
Effective Rate in Off Time
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.
Time frame: Baseline, 16 weeks after dosing
Clinical Global Impression (CGI)
Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement.
Time frame: Baseline, 16 weeks after dosing
Dystonia (at an Early Hour)
Change (LOCF) from baseline in occurrence of Dystonia (at an early hour).
Time frame: Baseline, 16 weeks after dosing
Dystonia (in the Daytime)
Change (LOCF) from baseline in occurrence of Dystonia (in the daytime).
Time frame: Baseline, 16 weeks after dosing
| Milestone | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Started | 168 | 167 | 85 |
| Completed | 142 | 144 | 68 |
| Not completed | 26 | 23 | 17 |
| Withdrew: Adverse event | 13 | 11 | 9 |
| Withdrew: Lack of efficacy | 2 | 1 | 5 |
| Withdrew: Withdrawal by subject | 6 | 4 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Discontinuation criteria | 3 | 4 | 0 |
| Withdrew: Physician decision | 2 | 2 | 1 |
Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score | -10.9 ± 8.1 | -9.5 ± 8.7 | -4.5 ± 9.7 |
Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing. UPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| 8 weeks after dosing | -9.7 ± 7.2 | -8.4 ± 8.1 | -5.5 ± 8.3 |
| 10 weeks after dosing | -9.9 ± 7.1 | -8.8 ± 8.3 | -5.3 ± 9.0 |
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing. UPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| UPDRS Part 2 Sum Score | -3.6 ± 4.1 | -2.9 ± 3.5 | -1.3 ± 3.4 |
Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day.
| Hours/day | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Off Time | -1.3 ± 2.9 | -2.0 ± 3.0 | -0.4 ± 2.7 |
Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Parkinson's Disease Sleep Scale-2 (PDSS-2) | -3.1 ± 6.8 | -3.4 ± 7.6 | -1.8 ± 7.0 |
Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.
| Hours/day | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| On Time | 1.3 ± 2.7 | 1.7 ± 2.9 | 0.2 ± 2.6 |
Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.
| Hours/day | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| On Time Without Dyskinesia Disturbing Daily Activities | 1.1 ± 2.9 | 1.6 ± 3.0 | 0.3 ± 2.6 |
Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time).
| Hours | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| On Time With Dyskinesia Disturbing Daily Activities | 1.3 ± 11.0 | 0.6 ± 7.8 | -0.2 ± 1.4 |
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.
| Percentage of participants | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| ≥20% decrease | 80.5 (74.4 to 86.6) | 69.1 (62.0 to 76.1) | 56.6 (46.0 to 67.3) |
| ≥30% decrease | 69.5 (62.5 to 76.6) | 60.6 (53.2 to 68.1) | 39.8 (29.2 to 50.3) |
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.
| Percentage of participants | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| ≥20% decrease | 65.2 (57.9 to 72.6) | 56.7 (49.1 to 64.3) | 47.0 (36.3 to 57.7) |
| ≥30% decrease | 55.9 (48.2 to 63.6) | 43.3 (35.7 to 50.9) | 28.9 (19.2 to 38.7) |
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.
| Percentage of participants | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| ≥20% decrease | 61.8 (52.7 to 70.9) | 65.5 (56.7 to 74.3) | 47.4 (34.4 to 60.3) |
| ≥30% decrease | 55.5 (46.2 to 64.7) | 61.9 (53.0 to 70.9) | 40.4 (27.6 to 53.1) |
Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement.
| Percentage of Participants | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Decreased | 50.3 | 49.1 | 30.9 |
| Decreased (by at least 2 points) | 8.0 | 8.5 | 3.7 |
| Increased | 3.1 | 4.2 | 4.9 |
| Increased (by at least 2 points) | 0 | 0 | 0 |
Change (LOCF) from baseline in occurrence of Dystonia (at an early hour).
| Percentage of participants | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Decreased | 10.4 | 10.9 | 7.4 |
| Decreased (by at least 2 events) | 1.8 | 4.2 | 2.5 |
| Increased | 1.2 | 3.0 | 3.7 |
| Increased (by at least 2 events) | 0 | 0.6 | 0 |
Change (LOCF) from baseline in occurrence of Dystonia (in the daytime).
| Percentage of Participants | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Decreased | 8.6 | 7.9 | 3.7 |
| Decreased (by at least 2 events) | 3.7 | 5.5 | 2.5 |
| Increased | 3.7 | 2.4 | 4.9 |
| Increased (by at least 2 events) | 1.8 | 0.6 | 1.2 |
Collected over 21 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPM 962 | — | 7/168 (4.2%) | 140/168 (83.3%) |
| Ropinirole | — | 5/167 (3%) | 99/167 (59.3%) |
| Placebo | — | 6/85 (7.1%) | 40/85 (47.1%) |
| Event | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Angina PectorisCardiac disorders | 0/168 | 0/167 | 1/85 |
| PneumoniaInfections and infestations | 0/168 | 0/167 | 1/85 |
| Urinary Tract InfectionInfections and infestations | 0/168 | 0/167 | 1/85 |
| Spinal Compression FractureInjury, poisoning and procedural complications | 1/168 | 0/167 | 1/85 |
| Carcinoma GastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/168 | 0/167 | 1/85 |
| Disease Parkinson'sNervous system disorders | 1/168 | 1/167 | 1/85 |
| Cerebral Artery EmbolismNervous system disorders | 0/168 | 0/167 | 1/85 |
| Embolism PulmonaryRespiratory, thoracic and mediastinal disorders | 0/168 | 0/167 | 1/85 |
| Gastric Ulcer BleedingGastrointestinal disorders | 0/168 | 1/167 | 0/85 |
| CholecystitisHepatobiliary disorders | 0/168 | 1/167 | 0/85 |
| Event | SPM 962 | Ropinirole | Placebo |
|---|---|---|---|
| Application Site ReactionGeneral disorders | 91/168 | 30/167 | 10/85 |
| NasopharyngitisInfections and infestations | 28/168 | 24/167 | 13/85 |
| DyskinesiaNervous system disorders | 27/168 | 23/167 | 1/85 |
| NauseaGastrointestinal disorders | 25/168 | 23/167 | 7/85 |
| Hallucination VisualPsychiatric disorders | 13/168 | 10/167 | 3/85 |
| ContusionInjury, poisoning and procedural complications | 7/168 | 2/167 | 6/85 |
| VomitingGastrointestinal disorders | 11/168 | 11/167 | 2/85 |
| SomnolencePsychiatric disorders | 11/168 | 9/167 | 2/85 |
| CystitisInfections and infestations | 3/168 | 3/167 | 4/85 |
| Orthostatic HypotensionVascular disorders | 5/168 | 7/167 | 4/85 |
6 subjects were excluded. Met the exclusion criteria: 2 of SPM962, 1 of ropinirole Lack of efficacy observation: 2 of SPM962, 1 of Placebo
| Age, Categorical(Participants) | SPM 962 | Ropinirole | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 71 | 52 | 28 | 151 |
| >=65 years | 93 | 114 | 56 | 263 |
| Age, Continuous(years) | SPM 962 | Ropinirole | Placebo | Total |
|---|---|---|---|---|
| Mean | 64.8 ± 8.8 | 67.0 ± 7.9 | 65.3 ± 7.9 | 65.8 ± 8.3 |
| Sex: Female, Male(Participants) | SPM 962 | Ropinirole | Placebo | Total |
|---|---|---|---|---|
| Female | 103 | 98 | 42 | 243 |
| Male | 61 | 68 | 42 | 171 |
| Region of Enrollment(participants) | SPM 962 | Ropinirole | Placebo | Total |
|---|---|---|---|---|
| Japan | 164 | 166 | 84 | 414 |
The record gives a start of Jun 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →